Daniel A Goldstein

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Topics

Prostate Cancer

Radiation Induced

Radical Prostatectomy

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Medical oncology (Northwood, London, England)

Journal of oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ian F Tannock, Daniel A Goldstein, Jonathan Ofer, Bishal Gyawali, Tomer Meirson
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Aaron P Mitchell, Daniel A Goldstein
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Ian F Tannock, Mark J Ratain, Daniel A Goldstein, Allen S Lichter, Gary L Rosner, Leonard B Saltz
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (9) (2021)
Daniel A Goldstein, Chen Mayer, Tzippy Shochat, Daniel Reinhorn, Assaf Moore, Michal Sarfaty, Rinat Yerushalmi, Hadar Goldvaser
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. Cancer medicine 9 (13) (2020)
Andrew H Briggs, Daniel A Goldstein, Erin Kirwin, Rachel Meacock, Ankur Pandya, David J Vanness, Torbjørn Wisløff
Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health economics 30 (3) (2020)
Assaf Moore, Ido Stav, Robert B Den, Noa Gordon, Michal Sarfaty, Victoria Neiman, Eli Rosenbaum, Daniel A Goldstein
The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. Journal of oncology 2019 (2019)
Ido Stav, Bishal Gyawali, Daniel A Goldstein
Duration of adjuvant immunotherapy-biologic, clinical and economic considerations. Medical oncology (Northwood, London, England) 35 (12) (2018)
Daniel A Goldstein, Usama Bilal, Vinay Prasad
Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is? Cancer 123 (20) (2017)